Prof Karjalainen received his MD, PhD from Helsinki University, late seventies. After five years of postdoctoral studies in USA, Dr Karjalainen joined the Basel Institute for Immunology, Basel, Switzerland where he stayed for almost twenty years untill its closure early this century. Dr Karjalainen joined Nanyang Technological University in 2006 where he is currently Professor at the School of Biological Sciences. Dr Karjalainen is an immunologist with special interests in inflammation, hematopoiesis and stem cell research.
Prof Karjalainen would be speaking on ‘In vivo ablation of cell lineages’ at 2pm on 20 March 2012 at BioPharma Asia Convention’s NTU SBS Symposium.
Come and hear what he would be covering:
Innate immune cells are crucial regulators of immune reactions. They control the intensity and types of the immune responses that have to be elicited in a given situation. Many acute and chronic inflammatory reactions are mainly mediated by innate (myeloid) cells and hence they are important targets for therapeutic effects in multitude of disorders.
We have developed methods whereby we can ablate (delete) in vivo specific subsets of mouse myeloid cells like macrophage or DC cell subpopulations in order to study their contribution in different infectious or chronic inflammatory settings. More specifically we have generated transgenic mouse lines that express human diphtheria toxin receptor (DTR) in different myeloid cell subpopulations. Diphtheria toxin (DT) is not toxic for mouse cells and therefore, mouse cells expressing human DTR can be specifically ablated upon DT injection. Further details are discussed.
Join us at NTU's SBS Symposium! 8 professors will be coming together to share their latest developments in the biopharmaceutical arena at this symposium co-located atÂ BioPharma Asia Convention.Â Pre-register to attend BioPharma Asia Convention today!